We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aurolife Pharma Cites Cyberattack for Missing Records
Aurolife Pharma Cites Cyberattack for Missing Records
The FDA issued a Form 483 with nine observations to generics manufacturer Aurolife Pharma following a six-week inspection of the company’s manufacturing facility in Dayton, N.J., from Oct. 25 through Dec. 7, in which the company attributed some of its data deficiencies to a cyberattack.